FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
MyCartis aims to enable basic and clinical researchers to accelerate biomarker testing through its next generation multiplex biomarker analysis platform Evalution™. This provides academic centres, laboratories and pharmaceutical companies with an unprecedented level of biomarker information very quickly, accurately and cost-effectively.
MyCartis originates from the business combination of Biocartis’ business unit Evalution™ and Pronota NV. A seasoned team of 50 employees is located in Lausanne (Switzerland) and Ghent (Belgium). MyCartis regroups all the competencies for development and commercialization of novel biomarker assays and system engineering to deliver unique solution for the life science industry.
MyCartis serves the research community and engages in licensing opportunities with companies aiming to develop their own commercial applications on the Evalution™ platform. Furthermore, MyCartis develops and validates novel applications with simpler assay formats and unique biomarkers for a range of diseases.
Evalution™ is MyCartis’ digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering high quality data and rapid results. Evalution™ provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.